[
  {
    "ts": null,
    "headline": "Mettler-Toledo price target lowered to $1,250 from $1,500 at BofA",
    "summary": "BofA analyst Michael Ryskin lowered the firm’s price target on Mettler-Toledo (MTD) to $1,250 from $1,500 and keeps a Neutral rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especial",
    "url": "https://finnhub.io/api/news?id=89a67907b97e783f06d5f95741d4bc221e6af31e019cd86cb4d7664997d886e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744725744,
      "headline": "Mettler-Toledo price target lowered to $1,250 from $1,500 at BofA",
      "id": 133922496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MTD",
      "source": "Yahoo",
      "summary": "BofA analyst Michael Ryskin lowered the firm’s price target on Mettler-Toledo (MTD) to $1,250 from $1,500 and keeps a Neutral rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especial",
      "url": "https://finnhub.io/api/news?id=89a67907b97e783f06d5f95741d4bc221e6af31e019cd86cb4d7664997d886e4"
    }
  }
]